TrialESMO open2023

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.

P du Rusquec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.